Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
Natera has achieved a significant milestone with over 100 peer-reviewed publications on Signatera, its personalized molecular residual disease (MRD) test. The studies, published in prestigious journals like Nature and Journal of Clinical Oncology, demonstrate excellent clinical performance and utility. Signatera, the most widely used MRD test in the U.S., has served more than 200,000 cancer patients. The company continues to expand its research pipeline with several phase III randomized clinical trials across various cancer types.
Natera ha raggiunto un traguardo significativo con oltre 100 pubblicazioni sottoposte a revisione tra pari riguardanti Signatera, il suo test molecolare personalizzato per la malattia residua (MRD). Gli studi, pubblicati su riviste prestigiose come Nature e Journal of Clinical Oncology, dimostrano un'eccellente performance clinica e utilità. Signatera, il test MRD più utilizzato negli Stati Uniti, ha assistito oltre 200.000 pazienti oncologici. L'azienda continua ad ampliare il suo programma di ricerca con diversi studi clinici randomizzati di fase III su vari tipi di cancro.
Natera ha alcanzado un hito significativo con más de 100 publicaciones revisadas por pares sobre Signatera, su prueba molecular personalizada para la enfermedad residual mínima (MRD). Los estudios, publicados en revistas prestigiosas como Nature y Journal of Clinical Oncology, demuestran un excelente rendimiento clínico y utilidad. Signatera, la prueba de MRD más utilizada en EE. UU., ha atendido a más de 200.000 pacientes con cáncer. La compañía sigue expandiendo su pipeline de investigación con varios ensayos clínicos aleatorizados de fase III en diferentes tipos de cáncer.
Natera는 개인화된 분자 잔여 질병(MRD) 검사인 Signatera에 대해 100편 이상의 동료 검토 출판물을 발표하며 중요한 이정표를 세웠습니다. Nature 및 Journal of Clinical Oncology와 같은 저명한 저널에 발표된 이 연구들은 우수한 임상 성능과 효용성을 보여줍니다. Signatera는 미국에서 가장 널리 사용되는 MRD 검사로, 20만 명 이상의 암 환자에게 서비스했습니다. 회사는 다양한 암 유형에 대한 여러 3상 무작위 임상 시험을 통해 연구 파이프라인을 계속 확장하고 있습니다.
Natera a atteint une étape importante avec plus de 100 publications examinées par des pairs sur Signatera, son test moléculaire personnalisé pour la maladie résiduelle minimale (MRD). Les études, publiées dans des revues prestigieuses telles que Nature et le Journal of Clinical Oncology, démontrent d'excellentes performances cliniques et utilité. Signatera, le test MRD le plus utilisé aux États-Unis, a servi plus de 200 000 patients atteints de cancer. L'entreprise continue d'élargir son pipeline de recherche avec plusieurs essais cliniques randomisés de phase III portant sur divers types de cancer.
Natera hat einen bedeutenden Meilenstein erreicht mit über 100 begutachteten Veröffentlichungen zu Signatera, seinem personalisierten molekularen Restkrankheitstest (MRD). Die Studien, die in renommierten Fachzeitschriften wie Nature und Journal of Clinical Oncology veröffentlicht wurden, zeigen eine hervorragende klinische Leistung und Nützlichkeit. Signatera, der am häufigsten verwendete MRD-Test in den USA, hat über 200.000 Krebspatienten betreut. Das Unternehmen erweitert weiterhin sein Forschungspipeline mit mehreren randomisierten klinischen Studien der Phase III in verschiedenen Krebsarten.
- Over 100 peer-reviewed publications validating Signatera technology
- Signatera has served more than 200,000 cancer patients in the U.S.
- Multiple validations published in top-tier medical journals
- Ongoing phase III clinical trials across multiple cancer types
- None.
Insights
The milestone of 100+ peer-reviewed publications for Signatera demonstrates significant scientific validation and market leadership in molecular residual disease (MRD) testing. Publications in prestigious journals like Nature and JAMA Oncology establish strong credibility. With 200,000+ cancer patients served, Signatera's market penetration and clinical adoption are substantial.
The ongoing phase III trials in multiple cancer types suggest potential expansion of clinical applications and insurance coverage. The extensive validation portfolio strengthens Natera's competitive position against other MRD test providers and supports continued market share growth. This scientific foundation is important for maintaining premium pricing and securing additional payor contracts.
Underscores the Company’s commitment to generating robust scientific evidence on its leading MRD technology
Multiple validation studies on Signatera have been published in top-tier journals like Nature, Nature Medicine, Nature Cancer, Journal of Clinical Oncology, Annals of Oncology, and JAMA Oncology. These include some of the largest and most comprehensive prospective studies of MRD testing to date.
In clinical studies, Signatera continues to demonstrate excellent performance, and evidence-based use of Signatera in a real-world setting exemplifies its clinical utility and potential in guiding clinical care. These impactful studies have not only paved the way for coverage across a broad range of cancer types and indications but have also led to increased adoption among the medical community.
“Natera has always had a focus on developing robust clinical evidence,” said Alexey Aleshin, MD, chief medical officer and general manager of oncology. “The ongoing delivery of high-quality data is critical to our mission as we work to positively impact cancer care for patients and their families. We want to thank our patients for participating in these studies and our collaborators for their partnership on these efforts.”
Signatera is the most widely used and extensively validated MRD test in the
About Signatera
Signatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard-of-care tools, and help optimize treatment decisions. The test is available for clinical and research use and is covered by Medicare for patients with colorectal cancer, breast cancer, ovarian cancer, and muscle-invasive bladder cancer, as well as for immunotherapy monitoring of any solid tumor. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in over 100 peer-reviewed papers.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241121159633/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
FAQ
How many peer-reviewed publications does Natera's Signatera (NTRA) have?
How many patients has Natera's Signatera (NTRA) helped?
What types of cancer is Natera (NTRA) conducting phase III trials for?
